News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Precision BioSciences Announces Allowance of Eleventh U.S. Patent Application Related to Genome Editing Nucleases


10/29/2012 6:36:02 AM

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application 13/457,041 (“the ‘041 Application”). The allowed claims relate to materials and substitutions used for the creation of enzymes capable of modifying endogenous locations within a complex genome. These materials and substitutions constitute an important aspect of Precision’s genome engineering technologies, known collectively as the Directed Nuclease Editor or DNE.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES